89
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)

, , , , , & show all
Pages 501-509 | Published online: 18 May 2015

References

  • SulakPJContinuous oral contraception: changing timesBest Pract Res Clin Obstet Gynaecol200822235537417892973
  • ClaytonAHSymptoms related to the menstrual cycle: diagnosis, prevalence, and treatmentJ Psychiatr Pract2008141132118212599
  • SulakPJScowRDPreeceCRiggsMWKuehlTJHormone withdrawal symptoms in oral contraceptive usersObstet Gynecol200095226126610674591
  • JensenJTParkeSMellingerUSerraniMMabeyRGJrHormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimateEur J Contracept Reprod Health Care201318427428323638631
  • KlippingCDuijkersITrummerDMarrJSuppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimenContraception2008781162518555813
  • MacìasGMerki-FeldGSParkeSMellingerUSerraniMEffects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II studyJ Obstet Gynaecol201333659159623919857
  • SponaJElsteinMFeichtingerWShorter pill-free interval in combined oral contraceptives decreases follicular developmentContraception199654271778842582
  • BitzerJHormone withdrawal-associated symptoms: overlooked and under-exploredGynecol Endocrinol201329653053523421366
  • World Health OrganizationMedical eligibility criteria for contraceptive use4th ed2010 Available from: http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf?ua=1Accessed 23 February 2015
  • EndicottJNeeJHarrisonWBlumenthalRQuality of Life Enjoyment and Satisfaction Questionnaire: a new measurePsychopharmacol Bull19932923213268290681
  • GuyWClinical Global ImpressionsNational Institute for Mental HealthECDEU Assessment Manual for PsychopharmacologyRockville, MDDHEW Pub1976218222
  • BachmannGSulakPJSampson-LandersCBendaNMarrJEfficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenoneContraception200470319119815325887
  • BelseyEMMachinDd’ ArcanguesCThe analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human ReproductionContraception1986342532603539509
  • SulakPWillisSKuehlTCoffeeAClarkJHeadaches and oral contraceptives: impact of eliminating the standard 7-day placebo intervalHeadache2007471273717355491
  • NormanGRSloanJAWyrwichKWInterpretation of changes in health-related quality of life: the remarkable universality of half a standard deviationMed Care200341558259212719681